Kufor-Rakeb Syndrome

REHOVOT, Israel, Jan. 9, 2023 /PRNewswire/ -- NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced highly positive results from the Phase III multi-center, randomized, double-blind double-dummy (DBDD) BouNDless trial. The trial, which evaluated ND0612 – a continuous, 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for Parkinson's Disease (PD) patients with motor fluctuations – met its primary endpoint of "Good ON" time.1 Following two sequential open-label periods to optimize oral LD/CD and ND0612, patients were randomized to either ND0612 or oral LD/CD for a 12-week DBDD period.4 Treatment with ND0612 demonstrated superiority over oral LD/CD, with a statistically significant difference (p<0.0001) of 1.72 hours in "Good ON" time. The trial also demonstrated positive and clinically meaningful results for the key secondary endpoint of "OFF" time (p<0.0001) and other secondary endpoints including the MDS-Unified Parkinson's Disease Rating Scale Part II score (MDS-UPDRS motor experiences of daily living sub-score) (p<0.0001); the Patient Global Impression of Change (PGIC) (p<0.0001); and the Clinical Global Impression of Improvement (CGI-I) (p<0.0001).1 "With these positive results for the primary endpoint and four secondary endpoints, ND0612 has confirmed its potential as an effective treatment strategy for Parkinson's disease patients with motor fluctuations, despite optimization of oral therapies," said Professor Alberto Espay, MD, FAAN, Primary U.S. Investigator of BouNDless and Director of the James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders at the University of Cincinnati. "Continuous subcutaneous LD/CD treatment shows promise to change the treatment paradigm and transform the lives of patients with Parkinson's disease." The systemic safety profile of ND0612 was consistent with the well-established safety profile of oral standard of care LD/CD.1 Out of the most common (≥5%) adverse events (AEs) reported in any treatment group during the DBDD period, some infusion site reactions (hematoma, infection and erythema) were more frequently reported in the ND0612 group compared to oral LD/CD, while "on and off phenomenon" and falls were less frequently reported in the ND0612 group compared to oral LD/CD. Only 6.3% of patients randomized to ND0612 discontinued the trial during the DBDD period due to any reason – including 5.5% due to AEs, compared to 6.1% and 3.1%, respectively, of patients randomized to oral LD/CD.1 "These results are meaningful to both patients and healthcare providers, as there will be a novel, minimally invasive, continuous subcutaneous LD/CD treatment option demonstrating encouraging efficacy and tolerability, thereby helping patients stay on treatment with better motor function – an important milestone leading to better health outcomes and less clinical burden for people with PD experiencing motor fluctuations," said Professor Olivier Rascol, Primary Investigator of BouNDless in Europe and Israel, Professor of Clinical Pharmacology at Toulouse University Hospital and chair of the French NS-Park clinical research network on Parkinson's disease. "We are extremely encouraged by the positive outcome of the Phase III BouNDless trial. People with Parkinson's disease experiencing motor fluctuations have limited options to manage their condition. These remarkable results confirm the potential of ND0612 as an effective and well-tolerated treatment option to better control motor fluctuations – addressing a significant, unmet need," said Tami Yardeni, EVP, Clinical Development, NeuroDerm. "We are thankful to everyone who participated in this important trial and remain committed to improving the quality of life for people with Parkinson's disease and their families." Analyses of results from the ongoing BouNDless trial complement the long-term safety data assessing ND0612 with up to 7 years of follow-up.5 Additional data will be presented at upcoming medical meetings; submissions to regulatory authorities are anticipated in the United States this year and later in the European Union. About Parkinson's Disease Parkinson's disease affects more than 10 million people worldwide.6 It is caused by decreasing dopamine signaling in the brain as dopaminergic brain cells die off.7,8 Levodopa is the most important replacement therapy for Parkinson's disease, administered together with a levodopa degradation inhibitor (usually carbidopa).2,8 Oral levodopa intake leads to fluctuating plasma concentrations, with high peaks and low troughs that contribute to the progressive emergence of disabling clinical oscillations over the day in the motor function of many people with Parkinson's disease.9 With disease progression, adjustments in oral levodopa therapy become less and less effective in managing such motor complications, leaving patients with limited treatment options that are highly invasive.9 About ND0612 ND0612 is a drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa for people with Parkinson's disease experiencing motor fluctuations. There is an ongoing unmet need for treatment innovation for people with Parkinson's disease, as oral levodopa/carbidopa treatments yield a variable and unfavorable pharmacokinetic profile to maintain a stable clinical response during the day.10 ND0612 is designed to improve the drugs' pharmacokinetic profiles by avoiding gastric involvement and maintaining stable and continuous therapeutic levodopa plasma concentrations. About NeuroDerm, Ltd. NeuroDerm is a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Israel, inspired to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. NeuroDerm Ltd. is a pharmaceutical and medical technology integrated company developing central nervous system (CNS) product candidates that are designed to address major deficiencies of current treatments. For additional information, please visit NeuroDerm's website at www.neuroderm.com or follow us on LinkedIn. About Mitsubishi Tanabe Pharma Corporation and Mitsubishi Chemical Group Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future." With the MISSION of "creating hope for all facing illness," MTPC is prioritizing work on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety, focusing on the disease areas of central nervous system and immuno-inflammation. For more information, go to https://www.mt-pharma.co.jp/e/. About Mitsubishi Tanabe Pharma GmbH Mitsubishi Tanabe Pharma GmbH, based in Düsseldorf, was founded in 2003 under the name Mitsubishi Pharma Deutschland GmbH as a subsidiary of Mitsubishi Pharma Europe Ltd. (London/UK) which is an affiliate of Mitsubishi Tanabe Pharma Cooperation in Japan. Germany was the first country representative to market products from its own research outside Asia.